Tagged with France,

pharma  Pfizer Global Established Products’ BU Head and  Hospira’s Director of Institutional Affairs tell us about Pfizer’s recent major acquisition of Hospira, their post-merger strategy for increasing market access, as well as the challenges faced by the French biosimilars market and what Pfizer-Hospira is doing to achieve the huge potential in…

Pharma The Head of the Department of Medical Oncology at the Pitié-Salpêtrière Hospital reveals how France is the only country in the world with universal and unlimited access to healthcare, how the oncology world in France is committed to changing the perception of cancer and why the only way to prevent…

pharma (© Sébastien Borda) The CEO of Novartis France reveals how the construction of a new French headquarters demonstrates a commitment to develop operations in the country, how the Huningue Biotechnology Centre is the group’s flagship biotech facility, and why having become the country’s number one pharmaceutical company, the goal is…

pharma The general manager of Astellas France and president of LEEM, the French Pharmaceutical Companies Association, reveals how the pharmaceutical industry worldwide has to take into account what is a fair price for innovation, the sum of a value price, based on what you are providing for the health of a…

Pharma The President of Fefis, and the recently elected President of Medicen Paris Region, a Paris-based business cluster, talks about the need to build the future of the French health economy, not on past and current assets but to develop new ones; reveals how there is now a growing awareness of the…

Pharma The director of GEMME reveals how the French generics market is young in comparison to other European countries – where generics were on the market twenty years before they became available in France, how today the French Ministry of Health is sending a clear signal about the importance of generics…

Pharma The Chairman & CEO of DBV Technologies reveals how they have developed a new therapeutic method and new technology in the form of a patch to treat various allergies. DBV received a “breakthrough” designation from the FDA for the design which meets safety standards that no other products currently being developed do.…

Pharma The President of Cristers discusses the history of generic drugs in France and what steps can be taken to increase generics penetration, while also outlining the ‘cooperative’ business model behind Cristers’ meteoric rise – with a sixty-fold increase in turnover in less than a decade – from its creation in…

Pharma Yves Bur reveals how the motivation behind his political engagement has been to raise awareness around the importance of improving the social security system. Bur also explains why having a real public health policy is another way of combatting the increase in health spending, and how France needs to reach…

Pharma The General Manager of LEEM talks about the association’s strategy based on three key points, innovation, attractiveness and efficiency; how the Mediator affair has placed a question mark on the championing of the pharma industry as a national asset; why both France and Europe are at turning point and what…

innovation Hakim Djaballah arrived to Institut Pasteur Korea in July 2014 with an aim to return to the French institute’s focus on infectious diseases. He outlines the complexities of Korea’s research industry and stresses the importance of knowledge-sharing for success.   What have been some of the most important changes made…

France Sandoz has set important trends in the pharmaceutical market, first by creating a leading global generics business under the umbrella of parent company Novartis, and secondly by investing heavily in biosimilars, becoming a pioneer in a fast-growing niche. How have these two steps helped reshape Sandoz internally? With the creation…